Drugs / AMG 301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03238781 | Sep 2017 → Oct 2018 | migraine disorder | Amgen | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03238781 ↗ |
| Action | Inhibit | “an inhibitor of the pituitary adenylate cyclase-activating polypeptide (PACAP)-1 (PAC1) receptor” PMID 33231489 ↗ Nov 2020 |
| Modality | Monoclonal antibody | “a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody” PMID 33231489 ↗ Nov 2020 |
| Route | Subcutaneous | “subcutaneous (SC) injections” NCT03238781 ↗ |